A Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Interferon Alfa-N3 Therapy in Addition to Standard of Care in Adults Hospitalized Due to Acute Severe Influenza.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Interferon alpha-n3 (Primary)
- Indications Influenza A virus H1N1 subtype; Influenza virus infections
- Focus Therapeutic Use
- 06 Jan 2011 In a company media release, Hemipherex announced that the UD FDA has lifted a clinical hold on this trial, following a review of a submission which provided complete response to the Agency's reasons for the clinical hold.
- 04 Aug 2010 New trial record